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Abstract
Background: The perceived risk/benefit balance of prescribed and over-the-counter (OTC) medicine, as well as
complementary therapies, will significantly impact on an individual’s decision-making to use medicine. For women
who are pregnant or breastfeeding, this weighing of risks and benefits becomes immensely more complex
because they are considering the effect on two bodies rather than one. Indeed the balance may lie in opposite
directions for the mother and baby/fetus. The aim of this paper is to generate a discussion that focuses on the
complexity around risk, responsibility and decision-making of medicine use by pregnant and breastfeeding women.
We will also consider the competing discourses that pregnant and breastfeeding women encounter when making
decisions about medicine.
Discussion: Women rely not only on biomedical information and the expert knowledge of their health care
professionals but on their own experiences and cultural understandings as well. When making decisions about
medicines, pregnant and breastfeeding women are influenced by their families, partners and their cultural societal
norms and expectations. Pregnant and breastfeeding women are influenced by a number of competing discourses.
“Good” mothers should manage and avoid any risks, thereby protecting their babies from harm and put their
children’s needs before their own – they should not allow toxins to enter the body. On the other hand,
“responsible” women take and act on medical advice – they should take the medicine as directed by their health
professional. This is the inherent conflict in medicine use for maternal bodies.
Summary: The increased complexity involved when one body’s actions impact the body of another – as in the
pregnant and lactating body – has received little acknowledgment. We consider possibilities for future research
and methodologies. We argue that considering the complexity of issues for maternal bodies can improve our
understanding of risk and public health education.
Background
The aim of this paper is to generate a discussion that
focuses on the complexity around risk, responsibility
and decision-making of medicine use by pregnant and
breastfeeding women. By medicines, we mean pre-
scribed, over-the-counter (OTC) and complementary
medicines [1].
The purpose of this commentary is to draw on both
the biomedical and sociocultural perspectives in recogni-
tion that these are usually discussed separately. We hope
our multidisciplinary approach can deepen the discus-
sion of this issue. To set the scene, we consider risk in
the context of medicine use and decision-making for
pregnant and breastfeeding women and the role of the
‘good mother’ discourse. We then examine the evidence
surrounding the use of medicines during pregnancy and
breastfeeding from three perspectives: the first from bio-
medicine, the second from the health care professional
and the third from women. We suggest that the per-
spectives of the biomedical and the expert health care
provider are generally privileged by public health cam-
paigns. The paper concludes with suggestions for future
research and the most appropriate methodologies to
explore this relatively uncharted area of health research.
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Our modern society has become increasingly concerned
with understanding, calculating, managing, reducing or
eliminating the risks associated with everyday life [2,3]
and it is within this context that pregnant and breast-
feeding women have a social and moral responsibility to
manage risk [4-6]. The perceived risk/benefit balance of
prescribed and OTC medicine, as well as complemen-
tary therapies will significantly impact on an individual’s
decision to use medicine. For the maternal body –
women who are pregnant or breastfeeding – this weigh-
ing of risks and benefits becomes immensely more com-
plex because they are considering the effect on two
bodies rather than one. Indeed the balance may lie in
opposite directions for the mother and baby/fetus.
Pregnancy and breastfeeding, while inherently very
private events, attract vast public attention and scrutiny.
Deborah Lupton wrote that “the pregnant woman is sur-
rounded by a complex network of discourses and prac-
tices directed at the surveillance and regulation of her
body” and that “risk is a central discourse” [7] (p. 60).
Helman pointed out that all cultures share beliefs about
the vulnerability of the mother and fetus during preg-
nancy and that this usually continues throughout the
early postpartum or lactation period” [8] (p. 46, original
emphasis). Medical technology has embraced this vul-
nerability and the use of technologies, such as ultra-
sound, has meant that the fetus has increasingly
acquired an individual identity that is separate from the
mother and that the intensification of the health and
well-being of the fetus has sometimes resulted in the
mother being viewed primarily as the “maternal environ-
ment” [7] (p. 62).
Yet, despite the separation of the mother and fetus,
the mother is responsible for her fetus’ health and well-
being. “Her body therefore, is constructed as doubly at
risk and she is portrayed as doubly responsible, for two
bodies” [7] (p. 63, our emphasis). In addition, Lupton
points out that pregnant women are expected to be
extremely attentive in monitoring their bodies to ensure
the health of their babies is not threatened in any way
[7]. This self-regulation is extended to include the
expectation that pregnant women and one could argue
“good mothers”, are vigilant in their attendance at
antenatal appointments and undergo all medical tests
and examinations suggested by their health care
professionals.
None of this is surprising when one considers the tha-
lidomide disaster of the late 1950s and early 1960s.
Pregnant women were prescribed thalidomide for morn-
ing sickness until it was recognised that it was a potent
teratogen resulting in deformities in thousands of babies
[9]. Since this time, women have been given strong mes-
sages about the importance of maintaining their health
and avoiding toxins that can transfer from mother to
baby. Pregnant women are even cautioned against sim-
ple analgesics such as paracetamol. Deborah Lupton
details how:
“women are told that as well as avoiding any con-
sumption of alcohol and tobacco (and illicit drugs
such as marijuana and cocaine), they have been
advised to give up tea, coffee and cola drinks, avoid
certain sugar substitutes, avoid spa baths, be wary of
microwave ovens, not use electric blankets, avoid
having diagnostic x-rays, be careful in using house-
hold cleaning products and insecticides and not take
prescription or over-the-counter therapeutic drugs
(even headache pills) if possible” [7] (p. 64).
The phenomenon of “intensive mothering” was identi-
fied by Sharon Hays [10] whereby women must mother
their children intensively to ensure they are seen to be
“good mothers”. More recent work has positioned this
phenomenon as contemporary motherhood [11,12] and
suggests it still holds considerable power in societies
such as Australia, the US and the UK [13]. Intensive
mothers are also risk averse in their parenting approach
[5] whilst recognising that “professional support” is
essential to risk management [4].
The “good mother”
Most pregnant and breastfeeding women are signifi-
cantly influenced by the discourse of the “good mother”
(and, in turn, intensive mothering) which is widely dis-
cussed in the research literature [14-18]. In essence,
good mothers protect their babies from harm and put
their children’s needs before their own [19] – which
includes pregnant women. On the other hand, “respon-
sible” women take and act on medical advice – they
should take the medicine as directed by their health
professional. This is the inherent conflict in medicine
use for maternal bodies. Women in our society feel that
they are ultimately responsible for producing a “perfect
baby” [20,21] and presumably feel responsible for main-
taining optimum infant health by providing breast milk
free of possible contaminants such as medicines. Others
have taken this further, arguing the rights of the baby or
fetus are always prioritised above the mother [22,23].
This has been linked to the shift in western cultures
during the middle of the 20
th century where the opti-
mum way to raise children requires a “good mother”
who anticipates and adapts to their children’s needs
[6,24-26].
Once pregnancy is confirmed, women are faced with a
multitude of decisions and risk assessments. They must
decide what to eat (and not eat), what to drink (and not
drink), what tests they will undergo (and what actions
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type of birth they want, how they will feed their infant,
and so it goes on. However, in making these decisions,
w o m e nb e c o m es o l e l yr e s p o n s i b l ef o rt h ew e l f a r eo f
their fetus. As Lupton writes, “there is no such thing as
‘no risk’ in pregnancy, but it is ultimately the woman’s
responsibility to ensure she has done all that she can to
minimise risk” [7] (p. 76).
As a result of the risk discourse that is prolific around
pregnancy, it is now regarded as a hazardous journey
that requires a high level of expert surveillance as well
as vigilance on behalf of the woman. However, one of
the “implications of this discourse is that the woman
who fails to heed expert advice is portrayed as posing a
risk to her foetus” [7] (p. 66). The 20
th saw the rise of
the “monster mother” discourse where women are
accused of causing harm to their children and fetuses
[27]. Tsing argues that this discourse has extended to
women who choose to give birth without medical assis-
tance, regardless of the reasons why women make such
decisions [27]. Others have identified that this discourse
reduces women to an “environment” [28-30] and that
while society may consider it irresponsible for indivi-
duals to neglect their own health, it may be considered
criminal for pregnant and breastfeeding women to place
the health of their fetus or baby at risk [7]. Western
societies’ condemnation of women who are perceived to
fail by not putting their unborn babies’ or children’s
needs ahead of their own is indicative of women’s social
positioning and exemplifies the privileging of biomedical
knowledge over the women’s own knowledge.
Discussion
Biomedical perspective
Need for medicines during pregnancy and lactation
Of course, the use of medicines in pregnant and breast-
feeding women may sometimes be essential to maintain
the health of the woman (and baby). Poorly managed
epilepsy in pregnancy can result not only in harm to the
mother, but an increased risk of miscarriage [9].
Untreated depression during pregnancy has been asso-
ciated with increased caesarean sections and higher
admissions to neonatal intensive care units [31], poor
decision-making such as increased alcohol use and
missed medical appointments [32], as well as difficulties
in bonding with the baby [33]. Despite the low risk of
birth defects associated with commonly used antidepres-
sants [34], many women are reported to discontinue
their treatment upon confirmation of pregnancy [35,36].
HIV infection is another example where treatments
contribute to the health of the mother. Furthermore,
treatment of HIV during pregnancy has, potentially,
another beneficiary: the baby. Use of antiretroviral
(ARV) medicine during pregnancy and as prophylaxis to
the baby, in addition to other interventions, can signifi-
cantly reduce mother-to-child transmission (MTCT) of
HIV to less than two percent [37]. However, there are
considerable side-effects associated with ARV medicine
and there is a history of toxicity, morbidity and mortal-
ity associated with its use early in the HIV epidemic.
This has led to considerable scepticism and concern
resulting in reduced uptake [38]; pregnant women have
been particularly cautious about ARV use [39,40].
It is not surprising that both clinicians and women
find decision-making difficult, given the lack of safety
data about medicine use in pregnant and breastfeeding
women. In the past, women were often completely
excluded from drug trials – the United States (US)
Food and Drug Administration (FDA) started advocat-
ing for women to be included in 1993 [41]. Although
w o m e nh a v eb e e ni n c l u d e di nd r u gt r i a l sm o r e
recently, pregnant and breastfeeding women are
usually still excluded. The reason given for this exclu-
sion was to protect the child [9]. The result is that
existing safety data are limited: whilst there are small
case series of women who have taken a particular
medicine in pregnancy or lactation, systematic long-
term follow-up remains lacking.
Actual risks for medicine use during pregnancy and
breastfeeding are small. The real number of medicines
proven to be teratogenic – that is an agent that irre-
versibly alters growth, structure or function of the
developing embryo or fetus [42] – remains fewer than
30 [43]. Looking at breastfeeding women, Anderson
and colleagues reviewed all published case studies of
adverse events in infants caused by medicines, prior to
June 2002 [44]. They evaluated 94 papers describing
adverse reactions in 100 infants, of which none were
“definite”, 47% were “probable”,a n d5 3 %w e r e“possi-
ble” [44]. A case report of neonatal death from mater-
nal codeine use has since been reported [45].
Obviously caution is needed but, considering the num-
bers of breastfeeding women who take medicines, the
risk is small.
It is important to note that drug transfer (from
mother to child) is not the same in pregnancy and
breastfeeding. Most drugs taken by women during preg-
nancy cross the placenta from the mother’sc i r c u l a t i o n
to the fetus by simple diffusion – resulting in drug
transfer to the fetal circulation up to 100% [46]. In con-
trast, the breastfed infant receives far less maternal med-
icine than the fetus does. Medicines in the mother’s
circulation may transfer into milk, but usually only in
small amounts: infant exposure to the drug is five- to
ten-fold less than during pregnancy [47,48]. (For more
information about drug transfer see additional file 1:
Pharmacokinetics of medicines in pregnancy and
breastfeeding).
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Health professionals’ perception of risk
Health professionals must also assess risk for their preg-
nant and breastfeeding patients. Lyerly and colleagues
found that risk perception affects medical decision-mak-
ing in pregnancy, pointing out that the tendency for
health care professionals has been to “pursue zero risk
to the fetus, independent of the absolute size of the risk,
of competing considerations, or of recognition that fetal
risk exists in other acceptable contexts” [49] (p. 981).
They cite the example of vaginal birth after caesarean
(VBAC), where caesarean section may be promoted in
order to reduce the risk of perinatal death, without con-
sidering that even for a primary vaginal birth or caesar-
ean section there are risks to the infant. They also
identified that the risks of intervening are given prece-
dence over the risks of failing to intervene. For example,
radiological investigations may be delayed in pregnant
women because of perceived potential harm from x-
rays, while the real risk of septicaemia from an undiag-
nosed ruptured appendix is ignored; fetal loss may be
more than 30% after a perforated appendix [49]. The
use of medicines is similar. Halting medicines in preg-
nancy, or avoiding them in lactation, can lead to wor-
sening maternal and therefore child health. Lyerly and
colleagues suggest that “It is the physician’s obligation
not to eliminate risk, but to help patients weigh risk,
benefit, and potential harm, informed by best scientific
evidence and guided by a patient-centred ethic” [49] (p.
982).
Health professionals are expected to be knowledgeable
about medicines, yet are unlikely to have received speci-
fic education about prescribing for pregnant and breast-
feeding women. Many pharmacology textbooks do not
support the use of medicines for breastfeeding women:
“it is prudent only to expose the infant to such risks if it
is absolutely essential” [50] (p. 412). A recent survey of
general practitioners (GPs), conducted by one of the
authors (LHA), found that some GPs advised women to
avoid breastfeeding while taking medicines like metroni-
dazole and ibuprofen, which are considered compatible
with breastfeeding [51]. Furthermore, our research has
shown that health professionals often rely on the safety
ratings given to medicines in pregnancy when making
decisions about prescribing for breastfeeding women
[51]. If health provider knowledge is poor, it is not sur-
prising that the general public has little understanding
of medicine use for breastfeeding women.
Decision making by health professionals
Our research suggests that decision-making for health
professionals appears to be a spectrum from a straight
f o r w a r dd e c i s i o n ,s u c ha st r e a t m e n to fm a s t i t i s ,t oa
complicated one requiring multiple inputs and consid-
eration [51]. We need to be aware that the focus of
medicine use is generally about risks. We need to bal-
ance evidence of danger with reassuring evidence [49].
For example, while alerting health professionals about
the need for caution with codeine in breastfeeding
women [52], we can explain other options for analgesia
and evidence for their compatibility with breastfeeding.
“Quality use of medicines” programs are active in
many countries, yet have not addressed the use of medi-
cines for women who are pregnant or breastfeeding. For
example, in the UK, the National Collaborating Centre
for Primary Care (NCCPC) has recently published a
guideline on involving patients in decisions about pre-
scribed medicines, yet fails to mention use of medicines
in pregnancy or lactation [53]. Similarly, the Canadian
online database of interventions to promote evidence-
based prescribing and medicines use [54] makes no spe-
cific mention of issues relevant to women.
Women’s perspectives
Women’s perception of risk
A few studies have examined pregnant and breastfeeding
women’s risk perceptions of commonly used medicines.
A Norwegian study found that most women overesti-
mated the teratogenic risk associated with medicine use
during pregnancy. Interestingly, they found that women
with a high perception of risk were more likely to be
older, more highly educated and primiparous, although
over 80% of the women had used drugs during preg-
nancy (most commonly paracetamol, penicillin and
medicine for reflux) [55]. Similarly, a study by Sanz et
al. [56], concluded that overestimated risk perception
among women and health professionals led to induced
abortions of healthy and wanted babies. Women’sp e r -
c e p t i o n so fr i s ko ft h eu s eo fa n t i d e p r e s s a n t sd u r i n g
pregnancy has also been explored with 87% of women
mistakenly believing that antidepressant use during
pregnancy increased the risk of congenital abnormalities
[57].
Increasingly, it seems that our society expects a
breastfeeding woman to be “pure”: her body and her
milk should be free from any form of contamination
[58]. It is not surprising then, that studies have found
that prescribing medicine to breastfeeding women may
lead to early cessation of breastfeeding or that a breast-
feeding mother may be denied treatment due to the
possible risk to her baby [47,59].
Women’s decision-making during pregnancy and
breastfeeding
Recently researchers have examined the complexities
surrounding women’s experiences of antenatal screen-
ing, for example pregnant women’s decision-making
processes with regard to antenatal screening for Down
syndrome [20]. The authors of this review of qualitative
studies on the topic have dismissed the Theory of
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jectory and suggested that the decision-making takes
place in a complex framework [20]. They plan to test
the framework using ethnography and choice modelling
research [20]. Pregnant women considering antenatal
testing are often confused by the estimates of risks they
are given: the risk of having a baby with Down syn-
drome, the risk for miscarrying secondary to testing,
and so on [20]. On the other hand, how much harder
would it be to make decisions when the potential risk of
taking medicine while pregnant or breastfeeding is not
quantified? Furthermore, the risks of the alternatives are
not stated; the potential hazards of infant formula are
rarely considered [60,61]. Often, formula feeding is such
a cultural norm that health professionals and families
have trouble recognising that this is an artificial food,
potentially contaminated with bacteria [61] and poten-
tially leading to adverse child health outcomes [62].
Public health discourse has increasingly framed perso-
nal health choices as social and moral issues [6,63] and
as one’s own responsibility to sustain one’sh e a l t h
[2,3,64]. We would extend this to pregnant and breast-
feeding women and suggest that many women now feel
responsible for producing and maintaining a healthy
child. This increased responsibility has resulted in
hyper-vigilant women going out of their way to avoid
any possible toxins while pregnant or breastfeeding.
With increased awareness of environmental contami-
nants on health [65], the list of potential impurities con-
tinues to increase.
Areas for research
Decision-making around the use of medicines for preg-
nant and breastfeeding women is an under-researched
area in both the biomedical/pharmacological as well as
the social context. Although the importance of the
health of mothers and babies should be self-evident, we
believe this is a neglected area. Chris Mulford has
argued that breastfeeding is invisible to the health care
system and in her list of “blind spots” is medicine use
for lactating women [66].
Pharmaceutical companies have traditionally avoided
involving women of reproductive age in drug trials
and, although women are now included in many trials,
pregnant and breastfeeding women continue to be
excluded. This appears to be an area that everyone
wants to steer clear of. Yet, pregnant and breastfeeding
women do have acute and chronic medical conditions
that may require medicines. We can see at least three
areas where research is needed: at the level of drug
testing, at the level of health professionals who are
responsible for prescribing and dispensing medicine
and at the level of the general public – in particular
the woman herself.
It is timely for pharmaceutical companies to consider
ways of determining whether medicines are compatible
with pregnancy and lactation. The US FDA has pro-
posed major revisions to labelling of prescription drugs
in order to provide better information about the effects
of medicines used in pregnancy and breastfeeding [67].
The current letter category for risks of drug use in preg-
nancy is inaccurate and overly simplistic [67].
We need a better understanding of the issues for
health professionals faced with decision-making when
the medicine is prescribed for one body, but may impact
on two. Where do they get their information? How
helpful do they find the information? How can this be
improved? Similarly, understanding the ways in which
pregnant and lactating women want to receive informa-
tion about risks of taking medicines is crucial. For
example, would women appreciate the quantification of
the risks of each possible adverse outcome? Would pre-
senting numerical risk information as a “thousand per-
son” graphic [68] be more useful than presenting as
numbers or percent (such as 1 in 1,000; 0.1%)? Could
the estimate of the chance of suffering no adverse out-
come be more useful? Alternatively, would women pre-
fer a description of the possible adverse outcomes
(without quantification) or a comparison with everyday
risks (such as the risk of a particular birth defect with-
out any known exposure to a teratogen, or the risk of
car accident)? Can we quantify the risks to the child for
premature cessation of breastfeeding and the introduc-
tion of infant formula? Would women like to be pro-
vided with this information? In addition to what
information and how women would like to receive it,
who would they like to provide it? The general practi-
tioner during the consultation? The pharmacist dispen-
sing the medicine? Written information from a
government department, health professional body or
health institution? There is a dearth of knowledge about
the type of information as well as the most appropriate
and effective way to convey it to pregnant and lactating
women but we would argue that information presented
to women should be woman-centred.
Beyond prescribed medicine, little is known about how
pregnant and breastfeeding women interpret risk and
make decisions about the use of social substances such
as nicotine and alcohol as well as illicit substances.
Insight into the decision-making of pregnant and breast-
feeding women can inform better public health mes-
sages, clinical practice and policy guidelines.
We suggest that qualitative methodologies are often
appropriate to address many of these research questions.
Best results will be achieved by conducting collaborative
interdisciplinary research, combining medicine, phar-
macy, public health, psychology, sociology and anthro-
pology. We also need to include the woman herself, in
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[69]. Women may wish to play a more active role in
decision-making (the “patient-empowerment model”,
rather than the biomedical-educational model) [70]. Pre-
vious research has found that consumers value informa-
tion that enables “an informed choice promoting their
autonomy; [consumers reported that] it was reassuring
and reduced concern, conflict and anxiety about
whether the medicine was the right one for them; and it
gave them confidence in taking medicines” [70] (p. 115)
and this may also be true for pregnant and breastfeeding
women.
Summary
Health research in general focuses on the mother or the
baby (usually it is the mother who gets lost). The com-
plexity of living in a body where one’s actions impact on
another body has not been recognised and is under-
researched. We are calling for the development of
research that focuses on the maternal body. This is
important because the themes of “purity” in pregnancy
[71] and breastfeeding [58], seem to be gaining momen-
tum and increasing people’sa n x i e t ya b o u tw h a tt h e
maternal body is exposed to.
Women must deal with competing interests (hers and
her baby’s) when making decisions about medicine use
in the pregnant and lactating body. However, when
making such decisions, pregnant and breastfeeding
women rely not only on the expert knowledge of their
health care professionals but on their own experiences
and socio-cultural understandings as well [7]. Women
are likely to be influenced by their families, partners,
their cultural and societal norms and expectations, but
also by discourses of risk, responsibility and good
motherhood.
W ea r g u et h a tc o n s i d e r i n gt h e s ei s s u e si nt h ec o m -
plexity of maternal bodies can improve understanding of
risk perception and decision-making concerning medi-
cine use for the population as a whole as well as provid-
ing a better understanding of the decisions made by
pregnant and breastfeeding women. In addition to
research on the safe use of medicines during pregnancy
and lactation, qualitative research is needed to explore
in-depth the quandaries that women and their health
care providers face when medicine is indicated for preg-
nant and breastfeeding women. Understanding decision-
making by women and by health professionals requires
suitable study methods (as recommended by the review
of antenatal screening for Down syndrome [20]).
While it may be helpful to conceptualise the “maternal
body” when examining medicine use in pregnant and
lactating women, it is over-simplistic to believe the
issues are always the same. The answer is not one
response for both pregnant and breastfeeding women.
Responses must be considered separately for the preg-
nant woman and the breastfeeding woman. Research to
help us understand the concerns of the women and
health professionals will help with planning salient edu-
cation programs for both groups.
Additional material
Additional file 1: Pharmacokinetics of medicines in pregnancy and
breastfeeding A description of what happens to medicines in the body
of women who are pregnant or breastfeeding.
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